Concurrent administration of vinorelbine with recombinant human granulocyte colony-stimulating factor: An effective method of increasing dose intensity

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 22, Issue 1, 1999, Pages 38-41

  Weiss, Arthur J ^a,c   Sabol, Jennifer ^b   Lackman, Richard D ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Concurrent administration; Dose intensification; Infusional therapy; Recombinant human granulocyte colony stimulating factor; Vinorelbine

Indexed keywords

DOXORUBICIN; FLUOROURACIL; IFOSFAMIDE; NAVELBINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BLOOD TOXICITY; CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; MALE; STOMATITIS; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; INFUSIONS, INTRAVENOUS; MALE; NEOPLASMS; VINBLASTINE;

EID: 0033494630     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199902000-00010     Document Type: Article

References (23)

1. American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the use of hematopoietic colony stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471-508.
2. Weiss AJ, Lackman RD. Dose intensification by the simultaneous use of rhG-CSF and anti-cancer chemotherapy. Int J Oncol 1995;6:329-32.
3. Weiss AJ, Lackman RD. Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor. Am J Clin Oncol 1997;20:63-8.
4. Ellis GK, Livingston RB. Augmented dose intensity with concurrent G-CSF and continuous 5FU, adriazycin and cyclophosphanide (FAC) chemotherapy for breast cancer [abstract]. Proceedings of the American Society of Clinical Oncology 1994;13:58.
5. Livingston RB, Ellis GK, Gralow JR, et al. Dose-intensive vinorelbine with concurrent granulocyte colony stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1997;15:1395-400.
6. Cannistra SA, Groshek P, Griffin JD. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and In the myeloid blast crisis phase of chronic myeloid leukemia. 1989; 3:328-34.
7. Vokes EE, Rosenberg RK, Jahanzeb M, et al. Multicenter phase II study of weekly oral vinorelbine for stage IV non-small cell lung cancer. J Clin Oncol 1995;13:637-44.
8. Lake D, Johnson E, Herndon JM. Green - Cancer and Leukemia Group (CALGB). Phase II trial of navelbine (NVA) in relapsed small cell lung cancer (SCLC) [abstract]. Proceedings of the American Society of Clinical Oncology 1997;16:473a.
9. Fields S, Burris H, Wilding G, et al. Evaluating the role of navelbine in hormone-refractory prostate cancer (HRPC): a clinical benefit model [abstract]. Proceedings of the American Society of Clinical Oncology 1994;13:235.
10. Bajetta E, Di Leo A, Biganzoli L, et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 1996; 14:2546-51.
11. Heron JF, George Kerbrat P, Chauvergne J, et al. Phase II study of navelbine as second or third line treatment in advanced ovarian carcinoma. In: Solal-Celigny P, ed. Navelbine (vinorelbine) updates and new trends. Montrouge, France: John Libbey Eurotext Ltd, 1991:231-6.
12. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
13. Miller LL. Current status of G-CSF in support of chemotherapy and radiotherapy. Oncology 1993;10:67-88.
14. Meropol NJ, Miller LL, Korn EL, et al. Severe myelosuppression resulting from concurrent administration of granulocyte colony stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992;84:1201-3.
15. Rowinsky E, Sartorius S, Grochow L, et al. Phase I and pharmacologic study of topetecan, an inhibitor of topoisomerase I with granulocyte colony-stimulating factor: toxicologic differences between concurrent and post-treatment G-CSF administration [abstract]. Proceedings of the American Society of Clinical Oncology 1992;11:116.
16. Kabaya K, Obuchi M, Watanabe M, et al. Experimental study on safety for granulopoiesis in simultaneous therapy with recombinant human granulocyte colony-stimulating factor and chemotherapy. Oncol Res 1995;7:165-71.
17. Toussaint C, Izzo J, Spielman S, et al. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. J Clin Oncol 1994;12:2102-12.
18. Manara MC, Scotlandi K, Serra M, et al. Absence of stimulatory effect of G-CSF on the growth of human sarcoma cells. Int J Oncol 1995;6:1011-4.
19. Douple EB. Platinum-radiation interactions. Natl Cancer Inst Monogr 1988;6:315-9.
20. Tannock IF. Treatment of cancer with radiation and drugs. J Clin Oncol 1996;14:3156-74.
21. Hancock SL. Intercurrent death after Hodgkins disease therapy in radiotherapy and adjuvant MOPP trials. Ann Intern Med 1988;109:183-7.
22. Eltringham JR, Fajardo LF, Stewart JR, et al. Investigation of cardiotoxicity in rabbits from adriamycin and fractionated cardiac irradiation. Preliminary results. Front Radiat Ther Oncol 1979;13:21.
23. Hryniuk WM, Bonadonna G, Valagressa P. The effect of dose intensity in adjuvant chemotherapy. In: Salmon SE, ed. Adjunctive chemotherapy of cancer. Vol. 5. Philadelphia: Grune and Stratton, 1987:13-23.